Home/ sante SANTEZemprocitinib, new JAK1 inhibitor, shows efficacy against refractory rheumatoid arthritisZemprocitinib, a selective JAK1 inhibitor, achieves its primary endpoints in treating refractory rheumatoid arthritis unresponsive to conventional therapies.Published 13sem·1 sourceNotable·updated 6sem Lire en françaisListen≈ 22sSpeed0.8×1×1.2×1.5×The factThis protein kinase inhibitor specifically targets the JAK1 pathway involved in chronic joint inflammation.The results open new therapeutic prospects for patients inadequately responding to current treatments.🔗Click the link to read an article on the topic:Medscape FR↗🧭Explore this topic#polyarthrite rhumatoïde#JAK1#inhibiteur#traitementWhat if you saw the whole news differently?Factae cross-checks hundreds of sources worldwide to keep only the fact, no opinion. Explore the front page.→Story timelineJun 18Zemprocitinib, new JAK1 inhibitor, reaches major clinical milestoneJun 19Zemprocitinib, new JAK1 inhibitor, shows efficacy against refractory rheumatoid arthritisthis articleFollow topic →↗ Share the newsAuto-synthesis from 1 media source · identified on June 19, 2026← Back to home